Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153681 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL14337652 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL495540 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL3227000 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL1676895 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL17369100 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL1489327 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL1676795 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL2153965 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL2155121 | 1.00 | HIF1A (0.75) | HIF1ATSHRFAAHTRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170000893-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170001950-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20160263254-A1 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES | BRACCO INTERNATIONAL B.V. (NL) | 2016-09-15 | — | — | US | disclosed |
| US-9393315-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20140294973-A1 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES | TAIWAN LIPOSOME COMPANY, LTD. (TW) | 2014-10-02 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294973-A1 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES | PTEN, LIPA, PHOSPHO1 | HIF1A 1780/4885TSHR 3384/4885FAAH 2338/4885 |
| US-20160263254-A1 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES | KDR, FLT4, PTAFR | HIF1A 698/4885TSHR 1302/4885FAAH 924/4885 |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | HIF1A 3069/4885TSHR 1224/4885FAAH 1316/4885 |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | HIF1A 3069/4885TSHR 1224/4885FAAH 1316/4885 |
| US-20170001950-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | HIF1A 3069/4885TSHR 1224/4885FAAH 1316/4885 |
| US-20170000893-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | HIF1A 3069/4885TSHR 1224/4885FAAH 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.